PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT CONTRACT. JULY 9, 2022 - JULY 8, 2027

药物开发合同的纯度规格、储存和分发。

• 批准号: 10937279
• 负责人: SCOTT P RUNYON
• 金额: $ 46.6万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-09 至 2024-07-08
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10937279
• 关键词: Contracts; Development; Pharmaceutical Preparations; Specific qualifier value

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of drug addiction. The objective of this contract is to provide NIDA and other NIH Institutes (NINDS and NIMH) with a centralized confidential repository of compounds for evaluation as potential treatment agents, standards and screening agents. “This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”

国家药物滥用研究所(NIDA)治疗和医学后果司(DTMC)支持研究和开发治疗药物成瘾的新药。这样做的目的是 合同的目的是向NIDA和其他NIH研究所(NINDS和NIMH)提供一个集中的机密化合物储存库，用于作为潜在的治疗剂、标准和筛查剂进行评估。 这项研究是NIH帮助结束成瘾长期(Hear)倡议的一部分，该倡议旨在加快科学解决方案，以了解疼痛的基础，并加强临床疼痛管理。